Eversheds Sutherland has continued to invest in its European growth strategy with lateral partner hire, Anne Servoir, who joins the firm’s Paris-based Commercial Advisory team.

Specializing in pharmaceutical and regulatory law, Anne strengthens the global law firm’s offering with a dedicated practice focused on legal issues affecting the healthcare, pharmaceutical and biotechnology sectors.

Anne Servoir has more than 25 years’ experience advising leading pharmaceutical companies and start-ups in the pharmaceutical, biotech and medtech industries, both in France and internationally. She notably advises clients on their market access strategies, including early access to market, transition to standard reimbursement frameworks and pricing negotiations, as well as representing them in pre-litigation and litigation proceedings against decisions of regulatory authorities (including the ANSM and the CEPS).

Anne is also active in commercial litigation and has developed particular expertise in the field of medical cannabis, an area in which she has been closely involved since the early stages of its pilot program in France.

Anne joins an established and highly regarded Eversheds Sutherland team in France, known for its strong international reach and recognized expertise in the Healthcare and Life Sciences sector. Her arrival will further enhance the firm’s regulatory offering, responding to growing client demand across key areas including advertising, transparency obligations, patient support programs and health data protection.

Admitted to the Paris Bar since 1998, Anne holds a PhD in European Law from Université Nancy II. She began her career in the Competition and European Law team at CMS Francis Lefebvre, where she developed extensive expertise in regulated sectors, from telecommunications to the pharmaceutical industry. She then joined Intuity, a firm specializing in pharmaceutical and regulatory law, where she practised for nearly ten years until 2017, when she joined the Paris office of Hoyng Rokh Monegier, where she led the Regulatory Pharma practice.